Swedish biopharma company Calliditas Therapeutics AB (STO:CALTX) announced on Thursday that its partner Viatris Pharmaceutical Japan G.K. has initiated a Phase 3 clinical trial of Nefecon (VR-205) in Japanese patients with IgA nephropathy (IgAN).
The bridging study in Japan requires a limited number of Japanese patients and mirrors the design of the global NefIgArd trial.
A type of kidney disease, IgA nephropathy is a serious condition that affects an estimated 33,000 patients in Japan, with limited treatment options.
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Avacta Group partners with Tempus to enhance AI-driven oncology drug development
PharmaLogic opens new radiopharmaceutical facility in Salt Lake City
Astellas Pharma's VYLOY receives US FDA approval
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
OncoZenge partners with Pharmanovia for exclusive BupiZenge commercialization in EMENA regions
SHINE Technologies collaboration could result in new kidney and prostate cancer treatments
Elysium Health launches VISION for visual performance and eye health
IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial
Innovent Biologic meets primary endpoint in picankibart phase 2 study